ReviewAdvanced drug delivery reviews2023
Inorganic nanoparticles as scaffolds for bioorthogonal catalysts.
Review in Advanced drug delivery reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Bioorthogonal Photoactivation of 2-Nitrobenzyl Caged Doxorubicin Anticancer Prodrugs on Gold Nanostars.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Revolutionizing protein degradation: Harnessing nanoparticles for PROTAC delivery.Materials today. Bio · 2026Review
- Biomaterials in personalized drug delivery: innovations, challenges, and future directions.PeerJ · 2026Review
- Spatiotemporally Controlled Bioorthogonal Prodrug Activation for Precise Chemotherapy.Small science · 2026Article
- Engineered iron oxide nanoplatforms: reprogramming immunosuppressive niches for precision cancer theranostics.Molecular cancer · 2025Review
- Supramolecular Materials and Strategies for Bioorthogonal Chemical Transformations.Chemical reviews · 2025Review
- Gli pathway-targeted Co(iii) Schiff base complexes inhibit migration of basal cell carcinoma cells.RSC advances · 2025Article
- Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.Signal transduction and targeted therapy · 2025Review
- Exploring New Bioorthogonal Catalysts: Scaffold Diversity in Catalysis for Chemical Biology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Nanotechnology-driven synergy in cardio-oncology: enhancing tumor suppression and reducing cardiotoxicity.Frontiers in pharmacology · 2025Review
- Nanomaterial-enabled drug transport systems: a comprehensive exploration of current developments and future avenues in therapeutic delivery.3 Biotech · 2024Review
- Interfacial Rheological Investigation of Modified Silica Nanoparticles with Different Alkyl Chain Lengths at the n-Octane/Water Interface.Molecules (Basel, Switzerland) · 2024Article
- Potent and Versatile Biogenically Synthesized Alumina/Nickel Oxide Nanocomposite Adsorbent for Defluoridation of Drinking Water.ACS omega · 2024Article
- Interplay of chloride levels and palladium(ii)-catalyzedChemical science · 2024Article
- Modular Fabrication of Bioorthogonal Nanozymes for Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Modulation of Gold Nanoparticle Ligand Structure-Dynamic Relationships Probed Using Solution NMR.ACS nanoscience Au · 2024Article
- Lewis acid-driven self-assembly of diiridium macrocyclic catalysts imparts substrate selectivity and glutathione tolerance.Chemical science · 2023Article
- Biomimetic and bioorthogonal nanozymes for biomedical applications.Nano convergence · 2023Review
- Flexible Curcumin-Loaded Zn-MOF Hydrogel for Long-Term Drug Release and Antibacterial Activities.International journal of molecular sciences · 2023Article
- Nanoparticles loaded with natural medicines for the treatment of Alzheimer's disease.Frontiers in neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Bioorthogonal transition metal catalysts (TMCs) transform therapeutically inactive molecules (pro-drugs) into active drug compounds. Inorganic nanoscaffolds protect and solubilize catalysts while offering a flexible design space for decoration with targeting elements and stimuli-responsive activity. These "drug factories" can activate pro-drugs in situ, localizing treatment to the disease site and minimizing off-target effects. Inorganic nanoscaffolds provide structurally diverse scaffolds for encapsulating TMCs. This ability to define the catalyst environment can be employed to enhance the stability and selectivity of the TMC, providing access to enzyme-like bioorthogonal processes. The use of inorganic nanomaterials as scaffolds TMCs and the use of these bioorthogonal nanozymes in vitro and in vivo applications will be discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.